Cortical Disarray Measurement, a diffusion MRI metric, corresponded with autopsy-confirmed pathology in 36 FTLD cases. Associations differed by molecular subtype and were strongest in FTLD-TDP cases.
Key points
Sample size: 36 autopsy-confirmed cases (19 FTLD-tau, 17 FTLD-TDP).
Strongest MRI-pathology association observed in FTLD-TDP (TDP-43 pathology).
Sources
IMPALA trial long-acting ART noninferior to daily ART
IMPALA trial shows a long-acting antiretroviral regimen was noninferior to daily ART in Kenya, South Africa, and Uganda. Phase 3b trial results are linked.
Key points
Trial: phase 3b IMPALA in Kenya, South Africa, Uganda
Outcome: long-acting regimen noninferior to daily ART
Sources
- Original post
- Linked resource - Linked in the post
icotrokinra phase 2 trial shows higher week 12 response
icotrokinra in a phase 2 trial showed a clinical response at week 12 that was more common than placebo. The trial tested three oral doses once daily in moderately to severely active ulcerative colitis.
Key points
Clinical response at week 12 more common with icotrokinra than placebo.
Three tested doses of once-daily oral icotrokinra were used.
Sources
- Original post
- Linked resource - Linked in the post
